Bacterial cellular proteins

Bacterial cellular proteins encompass the complete array of proteins produced by bacteria, many of which are essential for their survival, growth, and ability to cause disease (Microbiology Society, 2023). These proteins serve as the primary targets for antimicrobial therapy, where drugs are designed to exploit structural differences between bacterial and human proteins to achieve selective toxicity (NIH, 2021). Key target classes include enzymes involved in cell wall peptidoglycan cross-linking, such as penicillin-binding proteins, and those involved in nucleic acid synthesis, like DNA gyrase and RNA polymerase. Additionally, the bacterial ribosome, composed of numerous ribosomal proteins and RNA, is a major target for protein synthesis inhibitors (StatPearls, 2023). Because this term refers to a vast and heterogeneous group of molecules across diverse species, it is classified as a broad category rather than a single specific therapeutic target. The ongoing evolution of these proteins through genetic mutation and horizontal gene transfer is the primary driver of global antibiotic resistance, necessitating the continuous discovery of new protein targets. Understanding these proteins is fundamental to developing both broad-spectrum and narrow-spectrum antibiotics.

Other names

Bacterial proteomeBacterial proteins

Antibacterial drugs target various bacterial cellular proteins to inhibit essential processes: beta-lactams inhibit penicillin-binding proteins (PBPs) to disrupt cell wall synthesis; fluoroquinolones inhibit DNA gyrase and topoisomerase IV to block DNA replication; and macrolides or aminoglycosides bind to ribosomal proteins/RNA to inhibit translation (StatPearls, 2023; NIH, 2021).